Wade, Ros; Rose, Micah; Neilson, Aileen; Stirk, Lisa; … - In: PharmacoEconomics 31 (2013) 10, pp. 841-852
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of ruxolitinib (Novartis) to submit clinical and cost-effectiveness evidence for ruxolitinib within its licensed indication (the treatment of disease-related splenomegaly or symptoms in adult patients with...